Earnings release
Page 1
Exhibit 99.1 INFLARX N.V . UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2025 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V . and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial statements are presented in euros (€). InflaRx N.V . is a company limited by shares, incorporated and domiciled in Amsterdam, The Netherlands. Its registered office and principal place of business is in Germany, 07745 Jena, Winzerlaer Str. 2 F-1
Page 2
Index to unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025 Unaudited condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2025 and 2024 F-3 Unaudited condensed consolidated statements of financial position as of September 30, 2025 and December 31, 2024 F-4 Unaudited condensed consolidated statements of changes in shareholders’ equity for the three and nine months ended September 30, 2025 and 2024 F-5 Unaudited condensed consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024 F-6 Notes to the unaudited condensed consolidated financial statements F-7 1. Summary of significant accounting policies and other disclosures F-7 a) Reporting entity and the Group’ s structure F-7 b) Basis of preparation F-7 2. Revenues F-8 3. Cost of sales F-8 4. Sales and marketing expenses F-8 5. Research and development expenses F-8 6. General and administrative expenses F-9 7. Other income F-9 8. Net financial result F-9 9. Inventory F-10 10. Other assets F-10 11. Tax receivables F-11 12. Financial assets and financial liabilities F-11 13. Trade payables and other accrued liabilities F-12 14. Cash and cash equivalents F-12 15. Equity F-12 16. Share-based payments F-13 a) Equity settled share-based payment arrangements F-13 b) Share-based payment expense recognized F-14 c) Share options exercised F-14 17. Protective foundation F-14 F-2
Page 3
InflaRx N.V . and subsidiaries Unaudited condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2025 and 2024 For the three months ended September 30, For the nine months ended September 30, Note 2025 (unaudited) 2024 (unaudited) 2025 (unaudited) 2024 (unaudited) (in €, except for share data) Revenues 2 23,830 123,819 63,262 166,212 Cost of sales 3 (333) 72,555 (2,409,207) (496,119) Gross profit (loss) 23,497 196,374 (2,345,945) (329,907) Sales and marketing expenses 4 (1,169,529) (1,707,748) (3,640,855) (4,995,915) Research and development expenses 5 (6,240,825) (11,140,152) (20,460,104) (28,458,832) General and administrative expenses 6 (2,618,844) (2,809,032) (10,960,934) (9,614,281) Other income 7 537,093 101,108 2,016,128 153,839 Other expenses (8,397) (589) (8,423) (297) Operating result (9,477,004) (15,360,039) (35,400,131) (43,245,392) Finance income 8 438,134 768,326 1,454,119 2,522,475 Finance expenses 8 (14,359) (5,032) (21,800) (15,876) Foreign exchange result 8 (21,127) (2,847,692) (4,799,940) (311,905) Other financial result 8 (3,174,451) — 3,788,647 103,285 Income taxes (12,282) (5,217) (12,282) (5,217) Income (loss) for the period (12,261,089) (17,449,654) (34,991,387) (40,952,630) Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods: Exchange differences on translation of foreign currency (12,340) (75,418) (276,611) (72,582) Total comprehensive income (loss) (12,273,429) (17,525,072) (35,267,998) (41,025,212) Share information Weighted average number of shares outstanding 67,747,130 58,883,272 66,285,299 58,883,272 Income (loss) per share (basic/diluted) (0.18) (0.30) (0.53) (0.70) The accompanying notes are an integral part of these condensed consolidated financial statements. F-3
Page 4
InflaRx N.V . and subsidiaries Unaudited condensed consolidated statements of financial position as of September 30, 2025 and December 31, 2024 Note September 30, 2025 (unaudited) December 31, 2024 (in €) ASSETS Non-current assets Property and equipment 309,692 256,280 Right-of-use assets 932,329 758,368 Intangible assets 46,181 50,781 Other assets 10 164,457 204,233 Financial assets 12 237,376 3,092,290 Total non-current assets 1,690,035 4,361,952 Current assets Inventories 9 5,071,345 6,897,666 Current other assets 10 5,385,399 5,103,402 Other assets from government grants and research allowance 10 6,399,161 5,081,772 Tax receivables 11 1,965,798 1,735,335 Financial assets 12 38,197,197 34,462,352 Cash and cash equivalents 14 6,448,117 18,375,979 Total current assets 63,467,015 71,656,505 TOTAL ASSETS 65,157,050 76,018,457 EQUITY AND LIABILITIES Equity Issued capital 15 8,129,656 7,122,205 Share premium 348,956,615 334,929,685 Other capital reserves 48,300,254 44,115,861 Accumulated deficit (367,183,608) (332,192,221) Other components of equity 7,163,899 7,440,510 Total equity 45,366,815 61,416,039 Non-current liabilities Lease liabilities 700,144 399,066 Other liabilities 13 36,877 36,877 Total non-current liabilities 737,021 435,943 Current liabilities Trade and other payables 12 9,228,118 11,394,232 Lease liabilities 270,718 406,020 Employee benefits 1,509,001 2,064,678 Liabilities to warrant holders 7,703,773 — Other liabilities 13 341,604 301,544 Total current liabilities 19,053,214 14,166,475 Total Liabilities 19,790,235 14,602,417 TOTAL EQUITY AND LIABILITIES 65,157,050 76,018,457 The accompanying notes are an integral part of these condensed consolidated financial statements. F-4
Page 5
InflaRx N.V . and subsidiaries Unaudited condensed consolidated statements of changes in shareholders’ equity for the nine months ended September 30, 2025 and 2024 (in €, except for share data) Note Shares outstanding Issued capital Share premium Other capital reserves Accumulated deficit Other compo- nents of equity Total equity Balance as of January 1, 2025 59,351,710 7,122,205 334,929,685 44,115,861 (332,192,221) 7,440,510 61,416,039 Loss for the period — — — — (34,991,387) — (34,991,387) Exchange differences on translation of foreign currency — — — — — (276,611) (276,611) Total comprehensive loss — — — — (34,991,387) (276,611) (35,267,998) Issuance of ordinary shares 8,395,420 1,007,450 15,136,235 — — — 16,143,686 Transaction costs for ordinary shares — — (1,109,305) — — — (1,109,305) Equity-settled share-based payments 16 — — — 4,184,393 — — 4,184,393 Balance as of September 30, 2025 67,747,130 8,129,656 348,956,615 48,300,254 (367,183,608) 7,163,899 45,366,815 Balance as of January 1, 2024 58,883,272 7,065,993 334,211,338 40,050,053 (286,127,819) 7,382,166 102,581,730 Loss for the period — — — — (40,952,630) — (40,952,630) Exchange differences on translation of foreign currency — — — — — (72,582) (72,582) Total comprehensive loss — — — — (40,952,630) (72,582) (41,025,212) Issuance of common shares — — — — — — — Transaction costs — — — — — — — Equity-settled share-based payments 16 — — — 3,725,907 — — 3,725,907 Balance as of September 30, 2024 58,883,272 7,065,993 334,211,338 43,775,960 (327,080,450) 7,309,584 65,282,425 *unaudited The accompanying notes are an integral part of these condensed consolidated financial statements. F-5
Page 6
InflaRx N.V . and subsidiaries Unaudited condensed consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024 For the nine months ended September 30, Note 2025 (unaudited) 2024 (unaudited) (in €) Operating activities Loss for the period (34,991,387) (40,952,630) Adjustments for: Depreciation & amortization of property and equipment, right-of-use assets and intangible assets 328,594 374,377 Net finance income 8 (421,026) (2,297,978) Share-based payment expense 16 4,184,393 3,725,907 Net foreign exchange differences and other adjustments 1,516,352 10,930 Changes in: Other assets from government grants and research allowances (1,317,389) — Other assets and trade receivables 10 (472,685) 1,854,051 Employee benefits (555,677) (95,288) Other liabilities 13 40,059 (2,649,488) Trade and other payables 13 (2,166,114) (254,567) Inventories 9 1,826,321 1,648,925 Interest received 10 1,436,554 1,990,054 Interest paid (16,724) (16,183) Net cash used in operating activities (30,608,728) (36,661,890) Investing activities Purchase of intangible assets, property and equipment (113,645) (29,992) Purchase of current financial assets (46,100,315) (27,835,062) Proceeds from the maturity of financial assets 41,567,040 78,273,017 Net cash from / (used in) investing activities (4,646,921) 50,407,963 Financing activities Proceeds from issuance of ordinary shares 16,143,686 — Proceeds from pre-funded warrants 12,915,909 — Transaction costs from issuance of ordinary shares and pre-funded warrants (1,949,998) — Repayment of lease liabilities (284,857) (290,145) Net cash from / (used in) financing activities 26,824,740 (290,145) Net increase/decrease in cash and cash equivalents (8,430,908) 13,455,929 Effect of exchange rate changes on cash and cash equivalents (3,496,954) (17,934) Cash and cash equivalents at beginning of period 18,375,979 12,767,943 Cash and cash equivalents at end of period 14 6,448,117 26,205,938 The accompanying notes are an integral part of these condensed consolidated financial statements. F-6
Page 7
InflaRx N.V . and subsidiaries Notes to the unaudited condensed consolidated financial statements 1. Summary of significant accounting policies and other disclosures a) Reporting entity and the Group’ s structure InflaRx N.V . (the “Company” or “InflaRx”) is a Dutch public company with limited liability (naamloze vennootschap) with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce Business Register under CCI number 68904312. The Company’ s registered office is at Winzerlaer Straße 2 in 07745 Jena, Germany. Since November 10, 2017, InflaRx N.V .’ s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX. InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system by focusing on applying its proprietary anti-C5a and C5aR technologies to discover, develop and commercialize first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. These consolidated financial statements of InflaRx comprise the Group. b) Basis of preparation These interim condensed consolidated financial statements for the nine-month reporting period ended September 30, 2025, and 2024 have been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements. The condensed consolidated financial statements requires management to make judgments, estimates and assumptions which are the same as at year end. Estimates and underlying assumptions are reviewed on an ongoing basis. Accordingly, this report is to be read in conjunction with the financial statements in the Company’ s annual report for the year ended December 31, 2024 on Form 20–F. The interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the “Board of Directors”) on November 10, 2025. The financial statements are presented in euros (€). The euro is the functional currency of InflaRx N.V . and InflaRx GmbH. The functional currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar. All financial information presented in euros have been rounded to the nearest euro. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them or may deviate from other tables. The accounting policies adopted are consistent with those followed in the preparation of the Group’ s annual consolidated financial statements for the year ended December 31, 2024, except for the adoption of new standards effective as of January 1, 2025, as set out below. The Group has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective early. The following amendments were adopted effective January 1, 2025, and do not have a material impact on the consolidated financial statements of the Group: • Amendments to IAS 21 Effects of Changes in Foreign Exchange Rates: Lack of exchangeability The following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group’ s consolidated financial statements is being assessed: • Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, Classification and Measurement of Financial Instruments • Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, Contracts Referencing Nature- dependent Electricity • IFRS 18 Presentation and Disclosure in Financial Statements • Annual Improvements V olume 11
Page 8
F-7
Page 9
2. Revenues For the three months ended September 30, For the nine months ended September 30, 2025 (unaudited) 2024 (unaudited) 2025 (unaudited) 2024 (unaudited) (in €) Revenues 23,830 123,819 63,262 166,212 Total 23,830 123,819 63,262 166,212 For the three months ended September 30, 2025 and 2024, the Company realized revenues from product sales of GOHIBIC (vilobelimab) in the amount of €24 thousand and €124 thousand, respectively. For the nine months ended September 30, 2025 and 2024, the Company realized revenues from product sales of GOHIBIC (vilobelimab) in the amount of €63 thousand and €166 thousand, respectively. Revenues reported are sales to end customers (hospitals). All revenues are attributed to sales made in the United States. 3. Cost of sales For the three months ended September 30, For the nine months ended September 30, 2025 (unaudited) 2024 (unaudited) 2025 (unaudited) 2024 (unaudited) (in €) Cost of sales 333 (72,555) 2,409,207 496,119 Total 333 (72,555) 2,409,207 496,119 For the three months ended September 30, 2025 and 2024, the Company’ s cost of sales amounted to €0.0 million and €(0.1) million, respectively. For the nine months ended September 30, 2025 and 2024, the Company’ s cost of sales amounted to €2.4 million and €0.5 million, respectively. For the the nine months ended September 30, 2025 cost of sales primarily includes write-downs of unfinished goods held in inventory that exceed expected sales quantities and are likely to expire before they can be sold. Cost of sales during the three months ended September 30, 2024 was primarily related to a reversal of a previous write-down in the amount of €75 thousand due to a change in estimate of sales of goods prior to expiry of their shelf life. 4. Sales and marketing expenses During the three months ended September 30, 2025, the Group incurred €1.2 million (2024: €1.7 million) of sales and marketing expenses in the United States. These expenses are mainly composed of €0.4 million (2024: €0.5 million) in marketing expenses for GOHIBIC (vilobelimab) and of €0.5 million (2024: €0.5 million) in personnel costs. During the nine months ended September 30, 2025, the Group incurred €3.6 million (2024: €5.0 million) of sales and marketing expenses in the United States. These expenses are mainly composed of €1.6 million (2024: €1.2 million) in personnel costs and €0.2 million (2024: €2.0 million) in external services for distribution and €1.1 million (2024: €1.0 million) in marketing expenses for GOHIBIC (vilobelimab). 5. Research and development expenses During the three months ended September 30, 2025, the Group incurred €6.2 million (2024: €11.1 million) of research and development expenses. These expenses are mainly composed of €1.9 million (2024: €1.9 million) in personnel costs and €4.2 million (2024: €8.7 million) in external services for the Group’ s research and development projects.
Page 10
F-8
Page 11
During the nine months ended September 30, 2025, the Group incurred €20.5 million (2024: €28.5 million) of research and development expenses. These expenses are mainly composed of €6.9 million (2024: €6.5 million) in personnel costs and €12.5 million (2024: €19.6 million) in external services for the Group’ s research and development projects. 6. General and administrative expenses During the three months ended September 30, 2025, the Group incurred €2.6 million (2024: €2.8 million) of general and administration expenses. These expenses are mainly composed of €1.4 million (2024: €1.4 million) in personnel costs, €0.3 million (2024: €0.4 million) in legal, consulting and audit fees, €0.9 million (2024: €1.0 million) in other general and administrative expenses. During the nine months ended September 30, 2025, the Group incurred €11.0 million (2024: €9.6 million) of general and administration expenses. These expenses are mainly composed of €5.7 million (2024: €5.1 million) in personnel costs, €2.8 million (2024: €1.7 million) in legal, consulting and audit fees, €2.5 million (2024: €2.8 million) in other general and administrative expenses. 7. Other income Other income for the three months ended September 30, 2025 amounted to €0.5 million (2024: €0.1 million), mainly from earned research allowances attributable to eligible research and development expenses during the period. Other income for the nine months ended September 30, 2025 amounted to €2.0 million (2024: €0.2 million), mainly from earned research allowance attributable to eligible research and development expenses during the period. During the first nine months ended September 30, 2024, the Group did not record other income from research allowances. 8. Net financial result For the three months ended September 30, For the nine months ended September 30, 2025 (unaudited) 2024 (unaudited) 2025 (unaudited) 2024 (unaudited) (in €) Interest income 438,134 768,326 1,454,119 2,522,475 Interest expenses (493) (321) (1,260) (297) Interest on lease liabilities (13,865) (4,711) (20,540) (15,580) Financial result 423,776 763,294 1,432,319 2,506,599 Foreign exchange income 731,488 319,442 3,853,346 4,123,268 Foreign exchange expense (752,615) (3,167,134) (8,653,286) (4,435,173) Foreign exchange result (21,127) (2,847,692) (4,799,940) (311,905) Result of expected credit loss adjustment on marketable securities — — — 103,285 Result from the revaluation of pre-funded warrants at fair value (3,174,451) — 3,788,647 — Other financial result (3,174,451) — 3,788,647 103,285 Net financial result (2,771,803) (2,084,398) 421,026 2,297,979 F-9
Page 12
For the three months ended September 30, 2025, net financial result decreased by €0.7 million to a loss of €2.8 million from a loss of €2.1 million for the three months ended September 30, 2024. This decrease is mainlyattributable to the fair value revaluation of pre-funded warrants issued in February 2025 in the amount of €-3.2 million and to the foreign exchange result which increased by €2.8 million.. Financial result decreased by €0.3 million due to lower interest income on marketable securities, in each case, compared to the three months ended September 30,2024. The decrease is offset by an increase of the foreign exchange result of €2.8 million. For the nine months ended September 30, 2025, net financial result decreased by €1.9 million to a gain of €0.4 million in the nine months ended September 30, 2025 from a gain of €2.3 million in the nine months ended September 30, 2024. This decrease is mainly attributable to the decrease of the foreign exchange result by €4.5 million. Finance result decreased by € 1.1 million due to lower interest income on marketable securities. This effect is partially compensated by a gain of € 3.8 million from the fair value revaluation of pre-funded warrants, issued in February 2025. 9. Inventory As of September 30, 2025 (unaudited) As of December 31, 2024 (in €) Raw material and supplies 82,090 82,087 Unfinished goods 4,938,358 6,758,952 Finished goods 50,897 56,627 Total 5,071,345 6,897,666 As of September 30, 2025, inventory amounted to €5.1 million, which represents a decrease of €1.8 million compared to December 31, 2024. In the first nine months ended September 30, 2025, the Company recorded write downs of unfinished product of €2.4 million (€2.7 million for unfinished product as of December 2024) in cost of sales, due primarily to product quantities on-hand exceeding quantities expected to be sold prior to their expiry. 10. Other assets As of September 30, 2025 (unaudited) As of December 31, 2024 (in €) Non-current other assets Prepaid expenses 164,457 204,233 Total non-current other assets 164,457 204,233 Current other assets Prepayments on research & development projects 4,789,056 4,628,878 Prepaid expenses 568,819 354,948 Others 27,524 119,576 Total current other assets 5,385,399 5,103,402 Other assets from research allowances Current other assets from research allowances 6,399,161 5,081,772 Total other assets from research allowances 6,399,161 5,081,772 Total other assets 11,949,016 10,389,407 F-10
Page 13
As of September 30, 2025, prepayments on research and development projects amounted to €4.8 million compared to €4.6 million as of December 31, 2024, and consist of prepayments on CRO and CDMO contracts. Prepaid expenses consist mainly of prepaid D&O insurance expense for the year 2025, which will be recognized into general and administrative expenses pro rata over the year. As of September 30, 2025, other assets from research allowances were €6.4 million compared to €5.1 million as of December 31, 2024, which represent reimbursements the Company qualifies for under the German Research Allowance Act (government grant).The increase is due to additional receivables recognized for eligible expenses incurred in the nine months ended September 30, 2025 in the amount of €2.0 million and a payment received for the year 2020 in the amount of €0.7 million. 11. Tax receivables As of September 30, 2025, tax receivables amounted to €2.0 million (V AT: €0.4 million, income tax receivables: €1.6 million) compared to €1.7 million (V AT: €0.5 million, income tax receivables: €1.2 million) as of December 31, 2024. 12. Financial assets and financial liabilities Set out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of September 30, 2025 and December 31, 2024: As of September 30, 2025 (unaudited) As of December 31, 2024 (in €) Financial assets at amortized cost Non-current financial assets 237,376 3,092,290 Thereof marketable securities — 2,854,405 Current financial assets 38,197,197 34,462,352 Thereof marketable securities 37,924,121 33,969,390 Financial liabilities at amortized cost Trade and other payables 9,405,869 11,549,150 Financial liabilities at fair value Current liabilities to warrant holders 7,703,773 — In February 2025, the Company issued 6,750,000 pre-funded warrants to certain investors in the context of a public offering of securities. As of September 30, 2025, the fair value of the warrants amounted to €7.7 million (Level 1). As of September 30, 2025, the fair value of current and non-current financial assets (primarily quoted debt securities) amounted to €38.5 million (as of December 31, 2024: €42.6 million) (Level 1). The Group’ s debt instruments at amortized cost consist solely of quoted securities that are graded highly by credit rating agencies such as S&P Global and, therefore, are considered low credit risk investments. As of September 30, 2025, current and non-current financial assets increased by €0.9 million to €38.4 million compared to €37.6 million of December 31,2024. The increase is mainly due to the subsequent reinvestment of interest bearing bank deposits (cash and cash equivalents) in marketable securities (financials assets). As of September 30, 2025, trade and other payables decreased by €2.1 million to €9.4 million compared to €11.5 million as of December 31, 2024. As of December 31, 2024 the Company temporarily had higher trade payables from CRO’ s. F-11
Page 14
13. Trade payables and other accrued liabilities As of September 30, 2025 (unaudited) As of December 31, 2024 (in €) Accrued liabilities from R&D projects 6,098,290 6,609,925 Accrued liabilities from commercial activities 139,600 69,250 Accounts payable 2,089,466 3,413,064 Other accrued liabilities and payables 1,242,366 1,603,538 Total 9,569,722 11,695,777 Accrued liabilities from R&D projects include third party services from the Company’ s ongoing R&D projects that have not yet been invoiced to the Company as of the reporting date. 14. Cash and cash equivalents As of September 30, 2025 (unaudited) As of December 31, 2024 (in €) Short-term deposits Deposits held in U.S. dollars 3,029,751 13,408,478 Deposits held in euros 410,000 700,000 Total 3,439,751 14,108,478 Cash at banks Cash held in U.S. dollars 2,292,400 2,805,655 Cash held in euros 715,965 1,461,847 Total 3,008,365 4,267,501 Total cash and cash equivalents 6,448,117 18,375,979 As of September 30, 2025, cash and cash equivalents decreased by €11.9 million to €6.4 million compared to €18.4 million as of December 31, 2024. 15. Equity On June 30, 2023, the Company filed a Form F-3, or the 2023-Registration Statement, with the Securities Exchange Commission, or the SEC, with respect to the offer and sale of securities of the Company, which became effective on July 11, 2023. The aggregate initial offering price of the securities that the Company may offer and sell under this prospectus will not exceed $250.0 million. In June 2024, the Company subsequently filed a prospectus supplement with the SEC relating to an at-the-market program providing for the sale of up to $75.0 million of our ordinary shares over time pursuant a sales agreement with Leerink Partners LLC, or the Sales Agreement. In the nine months ended September 30, 2025, we issued 145,420 ordinary shares under our ATM program, resulting in $353 thousand in net proceeds. Following this issuance under the ATM program, the remaining value authorized for sale under the ATM program is $73.5 million. In February 2025, the Company completed an underwritten public offering of 8,250,000 ordinary shares at a public offering price of $2.00 per ordinary share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 6,750,000 ordinary shares. The public offering price for each pre-funded warrant was equal to the price per share at which the ordinary shares were sold to the public, minus $0.001, which is the exercise price of each pre-funded warrant. The warrants are only exercisable by cashless exercise; the amount of ordinary shares to be received upon cashless exercise of such warrants is dependent on the Company’ s market share price at the time of exercise. The net proceeds from the offering were €26.8 million ($28.0 million). The warrants have an indefinite expiration and are fully or partly exercisable at any time. F-12
Page 15
16. Share-based payments a) Equity settled share-based payment arrangements InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V . at the time of its IPO in November 2017: Number of share options 2025 2024 Outstanding as of January 1, 148,433 148,433 Exercised during the nine months ended September 30 — — Outstanding as of September 30, 148,433 148,433 thereof vested / exercisable 148,433 148,433 Under the terms and conditions of the share option plan 2016, InflaRx GmbH granted rights to subscribe for InflaRx GmbH’ s ordinary shares to directors, senior management, and key employees. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V . at the time of its IPO in November 2017: Number of share options 2025 2024 Outstanding as of January 1, 888,632 888,632 Exercised during the nine months ended September 30 — — Outstanding as of September 30, 888,632 888,632 thereof vested / exercisable 888,632 888,632 InflaRx also granted share options under the 2017 Long-Term Incentive Plan, or 2017 LTIP, subsequently to its IPO in November 2017. Certain stock options granted between 2017 and 2020 were issued with an eight-year option term and during the three months ended March 31, 2025, were extended to an option term of ten years. The total number of share options granted during the nine months ended September 30, 2025 under the 2017 LTIP was as follows: Number of share options 2025 2024 Outstanding as of January 1, 8,905,446 6,584,946 Granted during the nine months ended September 30, 2,452,000 2,275,000 Exercised during the nine months ended September 30, — — Forfeited during the nine months ended September 30, (110,500) (7,000) Outstanding as of September 30, 11,246,946 8,852,946 thereof vested / exercisable 9,977,446 7,196,446 The key information and assumptions related to share options granted during the nine months ended September 30, 2025 under the 2017 LTIP were as follows: Share options granted 2025 Number Fair value per option FX rate as of grant date Fair value per option Share price at grant date / Exercise price Expected volatility Expected life (midpoint based) Risk-free rate (interpola ted, U.S. sovereign strips curve) January 03 2,452,000 $ 1.86 0.971 € 1.81 $ 2.41 0.97 5.5 0.04435 2,452,000 Of the 2,452,000 options granted in the nine months ended September 30, 2025 (ended September 30, 2024: 2,275,000), 1,700,000 options (September 30, 2024: 1,615,000) were granted to members of the executive management or Board of Directors. Expected dividends are nil for all share options listed above. F-13
Page 16
b) Share-based payment expense recognized For the three months ended September 30, 2025, the Company has recognized €0.6 million (2024: €0.7 million) of share-based payment expense in the statements of operations and comprehensive loss. For the nine months ended September 30, 2025, the Company has recognized €4.2 million (2024: €3.7 million) of share-based payment expense in the statements of operations and comprehensive loss including €356 thousand (ended September 30, 2024: nil) for the extension of option for the eight year option terms to ten years. None of the share-based payment awards were dilutive in determining earnings per share due to the Group’ s loss position. c) Share options exercised During the nine months ended September 30, 2025, no shares (2024: nil) were issued upon the exercise of share options, resulting in no proceeds to the Company (ended September 30, 2024: nil). 17. Protective foundation According to the articles of association of the Company, up to 169,300,000 ordinary shares and up to 169,300,000 preferred shares with a nominal value of €0.12 per share are authorized to be issued. All shares are registered shares. No share certificates shall be issued. In order to deter acquisition bids, the Company’ s general meeting of shareholders approved the right of an independent foundation under Dutch law, or protective foundation, to exercise a call option pursuant to the call option agreement, upon which preferred shares will be issued by the Company to the protective foundation of up to 100% of the Company’ s issued capital held by others than the protective foundation, minus one share. The protective foundation is expected to enter into a finance arrangement with a bank or, subject to applicable restrictions under Dutch law, the protective foundation may request the Company to provide, or cause the Company’ s subsidiaries to provide, sufficient funding to the protective foundation to enable it to satisfy its payment obligation under the call option agreement. These preferred shares will have both a liquidation and dividend preference over the Company’ s ordinary shares and will accrue cash dividends at a pre-determined rate. The protective foundation would be expected to require the Company to cancel its preferred shares once the perceived threat to the Company and its stakeholders has been removed or sufficiently mitigated or neutralized. The Company believes that the call option does not represent a significant fair value based on a level 3 valuation since the preferred shares are restricted in use and can be cancelled by the Company. During the three months ended September 30, 2025, the Company expensed €15 thousand (2024: €12.5 thousand) of ongoing costs to reimburse expenses incurred by the protective foundation. During the nine months ended September 30, 2025, the Company expensed €45 thousand (2024: €38 thousand) of ongoing costs to reimburse expenses incurred by the protective foundation. F-14
Page 17
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’ s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes thereto, for the three and nine months ended September 30, 2025 and 2024, respectively, included as Exhibit 99.1 to the report on Form 6-K to which this discussion is attached as Exhibit 99.2. We also recommend that you read our “ITEM 5. Operating and financial review and prospects” and our audited consolidated financial statements for fiscal year 2024, and the notes thereto, which appear in our annual report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, or the SEC, on March 20, 2025. In addition, we recommend that you read any public announcements made by InflaRx N.V . The following discussion is based on our financial information prepared in accordance with IFRS as issued by the IASB, which may differ in material respects from generally accepted accounting principles in the United States and other jurisdictions. We maintain our books and records in euros. Unless otherwise indicated, all references to currency amounts in this discussion are in euros. We have made rounding adjustments to some of the figures included in this discussion and analysis. Accordingly, numerical figures shown as totals in some tables may not be arithmetic aggregations of the figures that precede them. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under “ITEM 3. Key Information––Risk factors” in the annual report and risks described in our subsequent SEC filings. Unless otherwise indicated or the context otherwise requires, all references to “InflaRx” or the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V . and its subsidiaries InflaRx GmbH and InflaRx Pharmaceuticals, Inc. Overview InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. Vilobelimab for the treatment of PG In May 2025, we announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in the study, with no unexpected adverse events noted by the IDMC. We are in the process of winding down the clinical study and expect to be able to analyze and to comment on the study results by the end of this fiscal year. Vilobelimab for the treatment of severe COVID-19 In April 2023, we received an EUA, from FDA for GOHIBIC (vilobelimab) for the treatment of COVID-19 in critically ill, invasively mechanically ventilated hospitalized adult patients. The EUA is supported by the previously announced results of the multicenter Phase 3 PANAMO trial, which demonstrated a relative reduction in 28-day all-cause mortality by 23.9%. Subsequently, in June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States under the EUA. In January 2025, the EC granted marketing authorization under exceptional circumstances for GOHIBIC (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced ARDS who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation with or without extracorporeal membrane oxygenation. 1
Page 18
GOHIBIC (vilobelimab) for ARDS In June 2025, BARDA announced enrollment of the first patient in the JUST BREATHE Phase 2 platform clinical trial investigating novel therapeutic candidates for ARDS. The clinical trial is being implemented by the PPD clinical research business of Thermo Fisher Scientific and aims to evaluate the safety and efficacy of three host-directed therapeutic candidates at up to 60 U.S. sites, targeting a total enrollment of 600 hospitalized adult patients with ARDS. Anti-C5aR inhibitor INF904 To expand the breadth of our anti-C5a/C5aR technologies, we are also developing INF904, a product candidate that targets the C5a receptor. In INF904, we discovered a small molecule C5aR inhibitor that in pre-clinical studies has shown potential for superior characteristics to the only approved C5aR inhibitor, avacopan. INF904 has provided higher plasma exposure in animals, including non-human primates, and improved inhibitory activity in a hamster neutropenia model compared to avacopan. Furthermore, in contrast to avacopan, in vitro experiments showed INF904 has substantially less inhibition of the cytochrome P450 enzymes 3A4/5 (CYP3A4/5). INF904 demonstrated potential for anti-inflammatory therapeutic effects in several preclinical disease models. In January 2024, we announced the positive results of a single and multiple ascending dose study with INF904 in healthy volunteers. In December 2024, we announced that the first patient was dosed in the Phase 2a basket study in chronic spontaneous urticaria, or “CSU”, and hidradenitis suppurative, or “HS”, with data expected by early Nobember. In May 2025, we announced the successful completion of the required sub-chronic and chronic toxicology studies for INF904. No safety signals of concern were identified, supporting the potential for long-term dosing in future clinical efforts. Additional required non-clinical studies remain ongoing as planned. INF904 is a promising product candidate for being developed in several disease areas of inflammation, where orally available therapeutics are not available or a medical need exists despite availability of other therapies. INF904 for the treatment of CSU We have been pursuing development of INF904 for the treatment of CSU in a Phase 2a trial. CSU is a debilitating and unpredictable skin disease characterized by intensely itchy hives / wheals and angioedema. The burden of this chronic disease is high and impacts sleep, mental health, quality of life and productivity due to absences from school and work. CSU is estimated to affect around 40 million people worldwide. CSU patients have been reported to show elevated C5a levels, a major activator of mast cells and basophils which are thought to be significant contributors to CSU pathogenesis. In addition, studies suggest that complement activation (including C5a) in CSU can lead to histamine release. Current treatments are limited, and a significant unmet need exists in a sizable proportion of patients. INF904 for the treatment of HS We have also been pursuing development of INF904 for the treatment of HS in a Phase 2a trial. HS is a chronic, recurrent, debilitating neutrophil-driven inflammatory disease that can persist for years and tremendously impacts quality of life; it is characterized by abscesses, nodules and draining tunnels which can flare and cause scarring. INF904 inhibits the known C5a-induced effects on neutrophil activation and tissue accumulation of immune cells, including generation of tissue damaging mechanisms (enzyme release and oxidative radical formation) as well as induction of NETosis – mechanisms thought to be involved in HS progression and draining tunnel formation. Clinical evidence with existing C5a/C5aR products also supports that blocking this pathway reduces lesion counts. Patients’ responses to treatment with approved anti-TNF-alpha or anti-IL17 drugs are known to wane over time in a significant number of cases; and treatment with new therapeutics acting through other molecular mechanisms are needed for these patients. Anti-C5a antibody IFX002 We are developing IFX002 for the treatment of chronic inflammatory diseases. IFX002 is a highly potent anti- C5a antibody, which binds to the same domain of the C5a protein as vilobelimab, but which has a higher humanization grade and altered pharmacokinetic properties compared to vilobelimab. IFX002 is currently in preclinical development. We consider IFX002 to be a life-cycle management product to vilobelimab, given the long remaining patent life of IFX002. 2
Page 19
Financial highlights As of September 30, 2025, we had available funds amounting to €44.4 million, composed of €6.4 million in cash and cash equivalents and €37.9 million in marketable securities. Of the €6.4 million cash and cash equivalents, €1.1 million are held in euros and €5.3 million are held in U.S. dollars. Marketable securities held in U.S. dollars have a nominal value of $38.0 million (€32.0 million), marketable securities held in EUR have a nominal value of €6.0 million. We believe that our current funds on hand will be sufficient to fund our planned operations into 2027. We anticipate that our expenses might increase if and as we: • continue research, preclinical and clinical development efforts, as applicable, for any existing and future product candidates, including vilobelimab, INF904 and IFX002; • actively seek to identify additional research programs and additional product candidates; • seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any; • establish and expand sales, marketing, distribution and other commercial infrastructure now and in the future to commercialize various products for which we may obtain marketing authorization or approval, if any; • require the scale-up and validation of the manufacturing process and the manufacturing of larger quantities of product candidates for clinical development and, potentially, commercialization; • collaborate with strategic partners to optimize the manufacturing process for vilobelimab, IFX002, INF904 and other pipeline products; • maintain, expand and protect our intellectual property portfolio; • hire and retain additional personnel, such as commercial, marketing, clinical, quality control and scientific personnel; and • add operational, financial and management information systems and personnel, including personnel to support our product development as well as commercialization and help us comply with our obligations as a public company. Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we are, or any future collaborator is, able to obtain full marketing authorization or approval for, and successfully commercialize, one or more of our product candidates. Successful commercialization will require achievement of key milestones, including completing clinical trials of vilobelimab, INF904 and any other product candidates, obtaining marketing authorization or approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our future collaborators, may obtain marketing authorization or approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of revenues, and if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenue that is large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. In order to succeed, we will need to transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition. 3
Page 20
Accordingly, we may seek to further fund our operations through public or private equity or debt financings or other sources, including strategic collaborations. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop vilobelimab or any additional product candidates. Our failure to become and remain profitable could depress the market price of our ordinary shares and could impair our ability to raise capital, pay dividends, expand our business, diversify our product offerings or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment. Sales and marketing expenses • Sales and marketing expenses have consisted principally of: • external services for distribution of GOHIBIC (vilobelimab) to build and maintain the necessary commercial and logistical infrastructure, including external sales professionals; • marketing activities; • employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’ role within the organization; and • professional services fees in conjunction with making GOHIBIC (vilobelimab) available to hospitals and patients in the U.S. Research and development expenses Research and development expenses have consisted principally of: • expenses incurred under agreements with CROs, contract manufacturing organizations, or CDMOs, consultants and independent contractors that conduct research and development, preclinical and clinical activities on our behalf; • employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’ role within the organization; and • professional fees for lawyers related to the protection and maintenance of our intellectual property. We expense research and development costs as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as status of patient enrollment or clinical site activations for measuring services received and efforts expended. Research and development activities are central to our business model. Our research and development expenses primarily relate to the following key programs: • Vilobelimab. Our expenses associated with vilobelimab have decreased in 2025 will continue to decrease compared to 2024, given the recent decision to stop our Phase 3 study in PG. However, we will still incur some costs associated to our clinical activities, including the wind down of the Phase 3 trial in PG. • INF904. We are developing INF904, a product candidate that targets C5aR. We expect to incur additional costs by advancing the clinical and non-clinical development of INF904. Specifically, we expect to incur expenses through the ongoing Phase 2 clinica trial. We plan to continue studying INF904 in complement-mediated, chronic autoimmune and inflammatory conditions where an oral low molecular weight compound might have advantages or is needed for patients and where oral delivery is the medically preferred route of administration. Initially targeted indications include CSU and HS. • IFX002. We are developing IFX002 for the treatment of chronic inflammatory indications. IFX002 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered PK properties compared to vilobelimab and is currently in pre-clinical development. Expenses for this program mainly consist of salaries, costs for preclinical testing conducted by CROs and costs to produce preclinical material. 4
Page 21
• Other development programs. Our other research and development expenses relate to our preclinical studies of other product candidates and discovery activities, expenses for which mainly consist of salaries, costs for production of preclinical compounds and costs paid to CROs. General and administrative expenses Our general and administrative expenses consist principally of: • employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’ role within the organization; • professional fees for auditors and consulting expenses not related to research and development activities; • professional fees for lawyers not related to the filing, prosecution, protection and maintenance of our intellectual property; • insurance expenses including directors and officers liability insurance premiums; and • cost of facilities, travel, communication and office expenses. 5
Page 22
Results of operations The information below was derived from our unaudited interim condensed consolidated financial statements included elsewhere herein. The discussion below should be read along with these unaudited interim condensed consolidated financial statements and our Annual Report. Comparison of the three months ended September 30, 2025 and 2024 three months ended September 30, 2025 2024 Change (in €) Revenues 23,830 123,819 (99,988) Cost of sales (333) 72,555 (72,888) Gross profit 23,497 196,374 (172,877) Operating expenses Sales and marketing expenses (1,169,529) (1,707,748) 538,218 Research and development expenses (6,240,825) (11,140,152) 4,899,327 General and administrative expenses (2,618,844) (2,809,032) 190,189 Total operating expenses (10,029,198) (15,656,932) 5,627,734 Other income 537,093 101,108 435,985 Other expenses (8,397) (589) (7,808) Operating result (9,477,004) (15,360,039) 5,883,035 Finance income 438,134 768,326 (330,192) Finance expenses (14,359) (5,032) (9,327) Foreign exchange result (21,127) (2,847,692) 2,826,565 Other financial result (3,174,451) — (3,174,451) Income taxes (12,282) (5,217) (7,065) Income (loss) for the period (12,261,089) (17,449,654) 5,188,565 Exchange differences on translation of foreign currency (12,340) (75,418) 63,078 Total comprehensive income (loss) (12,273,429) (17,525,072) 5,251,643 Revenues three months ended September 30, 2025 2024 Change (in €) Revenues 23,830 123,819 (99,988) Total 23,830 123,819 (99,988) For the three months ended September 30, 2025, we realized €24 thousand revenues from product sales of GOHIBIC (vilobelimab) compared to revenues in the amount of €124 thousand from product sales of GOHIBIC (vilobelimab) in the three months ended September 30, 2024. Revenues reported are sales to end customers (hospitals). All revenues are attributed to sales made in the United States. Cost of sales three months ended September 30, 2025 2024 Change (in €) Cost of sales 333 (72,555) 72,888 Total 333 (72,555) 72,888 Cost of sales during the three months ended September 30, 2024, was primarily related to a reversal of a previous write-down in the amount of €75 thousand due to a change in estimate of sales of goods prior to expiry of their shelf life.
Page 23
6
Page 24
Sales and marketing expenses three months ended September 30, 2025 2024 Change (in €) Third-party expenses 10,864 371,433 (360,569) Marketing expenses 418,327 543,520 (125,192) Personnel expenses 535,234 523,443 11,792 Legal and consulting fees 80,161 84,701 (4,540) Other expenses 124,943 184,652 (59,709) Total sales and marketing expenses 1,169,529 1,707,748 (538,218) Our sales and marketing expenses incurred for the three months ended September 30, 2025 decreased compared to the three months ended September 30, 2024 by €0.5 million to €1.2 million. This decrease is primarily due to lower cost in external services for distribution and marketing expenses. Research and development expenses three months ended September 30, 2025 2024 Change (in €) Third-party expenses 4,163,919 8,718,232 (4,554,313) thereof vilobelimab 2,093,617 3,511,413 (1,417,796) thereof INF904 2,063,640 5,138,756 (3,075,116) thereof non-allocated 6,662 68,063 (61,401) Personnel expenses 1,883,198 1,868,749 14,449 Other expenses 193,708 553,171 (359,463) thereof vilobelimab 70,377 189,968 (119,591) thereof INF904 52,672 57,238 (4,566) thereof non-allocated 70,659 305,965 (235,306) Total research and development expenses 6,240,825 11,140,152 (4,899,327) Our research and development expenses incurred for the three months ended September 30, 2025 decreased by €4.9 million to €6.2 million compared to the three months ended September 30, 2024. This decrease is primarily due to lower third-party expenses for clinical material and related manufacturing expenses. General and administrative expenses three months ended September 30, 2025 2024 Change (in €) Personnel expenses 1,391,741 1,365,179 26,562 Legal, consulting and audit fees 346,259 439,144 (92,884) Other expenses 880,844 1,004,710 (123,866) Total comprehensive income (Loss) 2,618,844 2,809,032 (190,189) 7
Page 25
Other income three months ended September 30, 2025 2024 Change (in €) Other income from government grants and research allowances 535,214 — 535,214 Further other income 1,879 101,108 (99,229) Total other income 537,093 101,108 435,985 Our other income for the three months ended September 30, 2025 increased by €0.4 million compared to the three months ended September 30, 2024 and primarily consists of research allowances under the “Forschungszulagengesetz” (Research Allowance Act) for the three months ended September 30,2025. Net financial result three months ended September 30, 2025 2024 Change (in €) Interest income 438,134 768,326 (330,192) Interest expenses (493) (321) (172) Interest on lease liabilities (13,865) (4,711) (9,154) Financial Result 423,776 763,294 (339,519) Foreign exchange income 731,488 319,442 412,046 Foreign exchange expense (752,615) (3,167,134) 2,414,519 Foreign exchange result (21,127) (2,847,692) 2,826,565 Result from the revaluation of pre-funded warrants at fair value (3,174,451) — (3,174,451) Other financial result (3,174,451) — (3,174,451) Net financial result (2,771,803) (2,084,398) (687,405) For the three months ended September 30, 2025, net financial result decreased by €0.7 million to a loss of €2.8 million from a loss of €2.1 million for the three months ended September 30, 2024. This decrease is mainly attributable to the fair value remeasurement of pre-funded warrants issued in February 2025 in the amount of €3.2 million and to the foreign exchange result which increased by €2.8 million. Financial result decreased by €0.3 million due to lower interest income on marketable securities, in each case, compared to the three months ended September 30,2024. This effect is compensated by the increase of the foreign exchange result of €2.8 million. 8
Page 26
18. Comparison of the nine months ended September 30, 2025 and 2024 nine months ended September 30, 2025 2024 Change (in €) Revenues 63,262 166,212 (102,950) Cost of sales (2,409,207) (496,119) (1,913,088) Gross profit (2,345,945) (329,907) (2,016,038) Operating expenses Sales and marketing expenses (3,640,855) (4,995,915) 1,355,060 Research and development expenses (20,460,104) (28,458,832) 7,998,728 General and administrative expenses (10,960,934) (9,614,281) (1,346,653) Total operating expenses (35,061,892) (43,069,028) 8,007,135 Other income 2,016,128 153,839 1,862,289 Other expenses (8,423) (297) (8,126) Operating result (35,400,131) (43,245,392) 7,845,261 Finance income 1,454,119 2,522,475 (1,068,355) Finance expenses (21,800) (15,876) (5,924) Foreign exchange result (4,799,940) (311,905) (4,488,035) Other financial result 3,788,647 103,285 3,685,361 Income taxes (12,282) (5,217) (7,065) Income (loss) for the period (34,991,387) (40,952,630) 5,961,244 Exchange differences on translation of foreign currency (276,611) (72,582) (204,029) Total comprehensive income (loss) (35,267,998) (41,025,212) 5,757,214 Revenues nine months ended September 30, 2025 2024 Change (in €) Revenues 63,262 166,212 (102,950) Total 63,262 166,212 (102,950) For the nine months ended September 30, 2025, we realized €63 thousand revenues from product sales of GOHIBIC (vilobelimab) compared to revenues in the amount of €166 thousand from product sales of GOHIBIC (vilobelimab) in the nine months ended September 30, 2024. Revenues reported are sales to end customers (hospitals). All revenues are attributed to sales made in the United States. Cost of sales nine months ended September 30, 2025 2024 Change (in €) Cost of sales 2,409,207 496,119 1,913,088 Total 2,409,207 496,119 1,913,088 Our cost of sales during the nine months ended September 30, 2025 amounted to €2.4 million primarily due to higher inventory write-downs of €2.4 million. Write-downs were mainly due to quantities of unfinished goods on-hand exceeding quantities expected to be sold prior to expiry and were determined by a multiple scenario analysis. In the same period in 2024 write downs were lower due to a longer shelf-life of inventory as of September 30, 2024. 9
Page 27
Sales and marketing expenses nine months ended September 30, 2025 2024 Change (in €) Third-party expenses 231,807 2,002,332 (1,770,525) Marketing expenses 1,086,592 1,037,632 48,960 Personnel expenses 1,561,901 1,178,687 383,215 Legal and consulting fees 447,095 571,225 (124,130) Other expenses 313,459 206,039 107,421 Total sales and marketing expenses 3,640,855 4,995,915 (1,355,060) Our sales and marketing expenses incurred for the nine months ended September 30, 2025 decreased by €1.4 million compared to the nine months ended September 30, 2024 to €3.6 million. This decrease is primarily due to lower third party expenses mainly attributable to the in-sourcing of our sales staff which has previously been provided through a third party and offset by higher personnel expenses. Research and development expenses nine months ended September 30, 2025 2024 Change (in €) Third-party expenses 12,529,779 19,594,212 (7,064,433) thereof vilobelimab 4,541,892 9,953,583 (5,411,691) thereof INF904 7,856,210 9,395,938 (1,539,728) thereof non-allocated 131,677 244,691 (113,014) Personnel expenses 6,854,468 6,521,819 332,649 Other expenses 1,075,857 2,342,801 (1,266,944) thereof vilobelimab 408,600 1,071,350 (662,750) thereof INF904 165,696 164,188 1,508 thereof non-allocated 501,561 1,107,263 (605,702) Total research and development expenses 20,460,104 28,458,832 (7,998,728) Our research and development expenses incurred for the nine months ended September 30, 2025 decreased by €8.0 million to €20.5 million compared to the nine months ended September 30, 2024. This decrease is primarily due to lower third-party expenses for clinical material and related manufacturing expenses. General and administrative expenses nine months ended September 30, 2025 2024 Change (in €) Personnel expenses 5,678,129 5,082,285 595,844 Legal, consulting and audit fees 2,766,388 1,710,100 1,056,288 Other expenses 2,516,417 2,821,896 (305,480) Total comprehensive income (Loss) 10,960,934 9,614,281 1,346,653 Our general and administrative expenses incurred for the nine months ended September 30, 2025 increased by €1.3 million to €11.0 million, compared to the nine months ended September 30, 2024, mainly due to higher legal, consulting and audit expenses of €1.1 million and higher personnel expenses in the amount of €0.6 million. 10
Page 28
Other income nine months ended September 30, 2025 2024 Change (in €) Other income from government grants and research allowances 1,987,224 — 1,987,224 Further other income 28,905 153,839 (124,934) Total other income 2,016,128 153,839 1,862,289 Our other income for the nine months ended September 30, 2025 increased by €1.9 million compared to the nine months ended September 30, 2024. Our other income primarily consists of research allowances under the “Forschungszulagengesetz” (Research Allowance Act) in the nine months ended September 30, 2025. Net financial result nine months ended September 30, 2025 2024 Change (in €) Interest income 1,454,119 2,522,475 (1,068,356) Interest expenses (1,260) (297) (963) Interest on lease liabilities (20,540) (15,580) (4,961) Financial Result 1,432,319 2,506,599 (1,074,279) Foreign exchange income 3,853,346 4,123,268 (269,921) Foreign exchange expense (8,653,286) (4,435,173) (4,218,113) Foreign exchange result (4,799,940) (311,905) (4,488,035) Result of expected credit loss adjustment on marketable securities — 103,285 (103,285) Result from the revaluation of pre-funded warrants at fair value 3,788,647 — 3,788,647 Other financial result 3,788,647 103,285 3,685,361 Net financial result 421,026 2,297,978 (1,876,953) For the nine months ended September 30, 2025, net financial result decreased by €1.9 million to a gain of €0.4 million in the nine months ended September 30, 2025 from a gain of €2.3 million in the nine months ended September 30, 2024. This decrease is mainly attributable to the decrease of the foreign exchange result by €4.5 million. Financial result decreased by €1.1 million due to lower interest income on marketable securities. This effect is partially compensated by a gain of €3.8 million from the fair value remeasurement of pre-funded warrants, issued in February 2025. Liquidity and capital resources Since inception, we have incurred significant operating losses. For the nine months ended September 30, 2025, we incurred a net loss of €35.0 million. To date, we have financed our operations primarily through the sale of our securities. As of September 30, 2025, we had cash and cash equivalents in the amount of €6.4 million and financial assets in the amount of €38.4 million, comprised of marketable securities in the amount of €37.9 million and other financial assets amounting to €0.4 million. Our cash and cash equivalents primarily consist of bank deposit accounts and fixed U.S. dollar term deposits. 11
Page 29
Cash flows The table below summarizes our consolidated statement of cash flows for the nine months ended September 30, 2025 and 2024: nine months ended September 30, 2025 2024 (in €) Net cash used in operating activities (30,608,728) (36,661,890) Net cash from/ (used in) investing activities (4,646,921) 50,407,963 Net cash from/ (used in) financing activities 26,824,740 (290,145) Cash and cash equivalents at the beginning of the period 18,375,979 12,767,943 Effect of Exchange gains/ (losses) on cash and cash equivalents (3,496,954) (17,934) Cash and cash equivalents at the end of the period 6,448,117 26,205,938 1. Net cash from/used in operating activities The use of cash in all periods resulted primarily from our net losses, adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities decreased to €30.6 million in the nine months ended September 30, 2025, from €36.7 million in the nine months ended September 30, 2024. 2. Net cash from/used in investing activities Net cash from investing activities decreased by €55.1 million in the nine months ended September 30, 2025, mainly due to lower proceeds from maturity of marketable securities in the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024. These proceeds were reinvested into interest bearing bank deposits, which are accounted for as part of cash and cash equivalents. 3. Net cash from/used in financing activities Net cash from financing activities increased by €27.1 million in the nine months ended September 30, 2025, compared to the nine months ended September 30, 2024, due to a public offering of ordinary shares and pre-funded warrants in the nine months ended September 30, 2025. Funding requirements We expect our expenses associated with vilobelimab to decrease in 2025 compared to 2024, given the recent decision to terminate our Phase 3 study in PG. However, we will still incur some costs associated with our clinical activities, including those related to winding down the Phase 3 trial in PG. Furthermore, we will incur expenses, as we continue discussions with the FDA related to the planned submission of a BLA for full approval of GOHIBIC (vilobelimab) to treat severe COVID-19 and potentially additional related indications, continue to pursue commercializing of GOHIBIC (vilobelimab) under the EUA for emergency use as granted by the FDA. Lastly, we also incur expenses related to the manufacturing of clinical trial materials and in connection with further optimizing our manufacturing process for vilobelimab in compliance with regulatory standards. Furthermore, we also have established commercial scale production options and have initiated manufacturing campaigns to be able to serve the market needs in the United States under the granted EUA. We are advancing the development of INF904 through the ongoing Phase 2 clinical study, and expect to initiate additional clinical studies in the future. In parallel, we are also continuing with non-clinical development activities in relation to the manufacturing and additional non-clinical animal studies in order to prepare for this future development. If clinical data is supportive, we may seek marketing approval for any product candidates that we successfully develop. Additionally, we will validate and further develop the manufacturing process of our products to be able to apply for marketing authorization and to be able to provide a commercial-grade product. If we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to establishing sales, marketing, distribution, and other commercial infrastructure to commercialize such products. We will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. We believe that our existing cash and cash equivalents and financial assets will enable us to fund our operating expenses and capital expenditure requirements under our current business plan into 2027.
Page 30
12
Page 31
Until such time, if ever, that we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, royalty-based financings, future collaborations, strategic alliances, licensing arrangements and revenues from product sales. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the interest of our current shareholders will be diluted, and the terms of these securities may include voting or other rights that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. At-the-market program On June 28, 2024, we entered into a Sales Agreement with Leerink Partners LLC, to sell our ordinary shares from time to time through an at-the-market, or ATM, equity offering program of up to $75.0 million. In the nine months ended September 30,2025, we issued 145,420 ordinary shares under our ATM program, resulting in $353 thousand in net proceeds. Following this issuance under the ATM program, the remaining value authorized for sale under the ATM program is $73.5 million. For more information as to the risks associated with our future funding needs, see “ITEM 3. Key Information––Risk factors” in our Annual Report. Off-balance sheet arrangements As of September 30, 2025, and during the periods presented, we did not have any off-balance sheet arrangements other as described under “ITEM 5. Operating and financial review and prospects—off-balance sheet arrangements” in our Annual Report. Contractual obligations and commitments We do not have any, and during the periods presented we did not have any, contractual obligations and commitments other than as described under “ITEM 5. Operating and Financial Review and Prospects—Liquidity and capital resources––Contractual obligations and commitments” in the Annual Report. Quantitative and qualitative disclosures about market risk During the nine months ended September 30, 2025, there were no significant changes to our quantitative and qualitative disclosures about market risk from those reported in “ITEM 11. Quantitative and Qualitative Disclosures About Market Risk” in the annual report. During the nine months ended September 30, 2025, there were no significant changes to our quantitative and qualitative disclosures about market risk from those reported in “ITEM 11. Quantitative and Qualitative Disclosures About Market Risk” in the annual report. Critical judgments and accounting estimates There have been no material changes to the significant accounting policies and estimates described in “ITEM 5. Operating and Financial Review and Prospects—Critical judgments and accounting estimates” in the annual report. Critical accounting estimates There have been no material changes to the significant accounting policies and estimates described in Note B.2. to our consolidated financial statements in the annual report. 13
Page 32
Cautionary statement regarding forward looking statements This discussion contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this discussion and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We based these forward- looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about the following: • our ability to successfully secure distribution channels and commercialize GOHIBIC (vilobelimab) as a treatment for COVID-19 patients and the receptiveness of our ability to positively influence treatment recommendations by U.S. and European hospitals, guideline bodies and other third-party organizations; • our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab) in its approved or authorized indication or for vilobelimab and any other product candidates, under the EUA, and in the future if approved for commercial use in the United States, Europe or elsewhere; • our ability to successfully implement The InflaRx Commitment Program, the success of our future clinical trials for vilobelimab’ s treatment of other debilitating or life-threatening inflammatory indications, including ARDS and other indications, and any other product candidates, including INF904, and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; • the timing, progress and results of preclinical studies and clinical trials of vilobelimab, INF904 and any other product candidates, including for the development of vilobelimab in several indications, including to obtain full approval of GOHIBIC (vilobelimab) for COVID-19 and other virally induced ARDS, to treat HS and CSU and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally; • our interactions with and the receptiveness and approval by regulators regarding the results of clinical trials and potential regulatory approval or authorization pathways, including our BLA submission for GOHIBIC (vilobelimab); • the timing and outcome of any discussions or submission of filings for regulatory approval or authorization of vilobelimab, INF904 or any other product candidate, and the timing of and our ability to obtain and maintain full regulatory approval, the EUA and/or market authorization of vilobelimab or GOHIBIC (vilobelimab) for any indication; • our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases; • our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, INF904 and any other product candidates, and the scope of such protection; • whether the FDA, EMA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; • the success of our future clinical trials for vilobelimab, INF904 and any other product candidates and whether such clinical results will reflect results seen in previously conducted preclinical studies and clinical trials; • our expectations regarding the size of the patient populations for, the market opportunity for, the medical need for and clinical utility of vilobelimab, INF904 or any other product candidates, if approved or authorized for commercial use; • our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab and for the finished product GOHIBIC (vilobelimab) in the U.S. and Europe;
Page 33
14
Page 34
• our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; • our expectations regarding the scope of any approved indication for vilobelimab; • our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if, approved or authorized, any commercial sales; • if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory overview; • our ability to comply with enacted and future legislation in seeking marketing approval or authorization and commercialization; • our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; • our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors and other therapeutic products being developed in similar medical conditions in which vilobelimab, INF904 or any other of our product candidates is being developed or our industry; and • other risk factors discussed under the “ITEM 3. Key information––Risk factors” section of our Annual Report on Form 20-F. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should refer to the “ITEM 3. Key information––Risk factors” section of our Annual Report and risks described in our subsequent SEC filings for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this discussion or in our Annual Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the SEC after the date of this discussion. 15